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objective. To present a hypothetical model of the change in economic costs and health benefits to society that result from nosocomial
infection control programs.
design. We use a modeling framework to represent how 2 types of costs change with nosocomial infection control programs: costs
incurred by the hospital sector and community health services, as well as the private costs to patients. We also demonstrate how to value
the health benefits of nosocomial infection control programs, using quality-adjusted life years.
setting. Hypothetical modeling to incorporate the societal perspective.
subjects. A cohort of 50,000 simulated patients at risk of surgical site infection following total hip replacement.
intervention(s). A total of 8 hypothetical interventions that change costs and health outcomes among the cohort by preventing cases
of surgical site infection following total hip replacement.
results and conclusions. We demonstrate that when infection control interventions reduce economic costs and increase health
benefits, they should be adopted without further question. If, however, interventions increase economic costs and increase health benefits,
then the tradeoff between costs and benefits should be examined. Decision-makers should assess the cost per unit of health benefit from
infection control programs, consider the impact on health budgets, and compare infection control with alternative uses of scarce healthcare
resources.
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Those who set budgets for infection control in hospitals and
decide how those budgets should be allocated between in-
fection control programs must address 2 questions. First,
should current rates of healthcare-acquired infection be
reduced, and if so, by how much? Second, which infec-
tion control strategies are cost-effective and/or productively
efficient?
Answers can be found by studying how economic costs
and health benefits change with different infection control
strategies.1 By dividing the change in cost by the change in
health benefit for each strategy, the cost per unit of health
benefit is estimated. This measure is called an incremental
cost-effectiveness ratio (ICER). For example, a health inter-
vention that increases costs by $50,000 and extends life by
10 years would generate an ICER of $5,000 per life year
gained. Lower ICERs imply better value for money from
scarce healthcare resources. We provide a formal definition
of an ICER in the Appendix. The primary objective of this
article is to demonstrate how economic analyses and ICERs
can provide answers to both of the questions posed in the
previous paragraph. Although these questions were addressed
in a recent article,2 that analysis was conducted from the
perspective of the hospital administrator, and only the cost
of the infection control programs and the resulting changes
to hospital costs were included. The conclusions were that
infection control programs should be pursued up to the point
at which the marginal cost savings from preventing infections
compensate for the marginal costs of infection control, and
only cost-effective programs should be used. This implies that
some infection control programs are not cost-effective, and
should be rejected by decision makers. Although this model
is useful to those working in the hospital sector (ie, those for
whom the efficiency of the hospital is paramount), econo-
mists recommend that decisions about investing scarce
healthcare resources be based on a broader definition of both
costs and health benefits.3 Economic evaluation research
should reflect the values of all members of society and not
just the preferences of those who manage hospital services.
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table 1. Hypothetical Costs Associated With Surgical Site Infection (SSI) for 6 Competing In-
fection Control Strategies
Strategy,
ranked
by cost
Rate of
SSI, %
Costs in US$ (% of total cost)
Cost of
infection
control
Cost of infection
TotalTo hospital To CCS To patient
Status quoa 10.00 0 (0) 1,750,000 (65) 675,000 (25) 250,000 (10) 2,675,000
Option 6 6.00 299,611 (15) 1,070,388 (55) 412,864 (21) 152,913 (8) 1,935,776
Option 3 7.50 523,487 (20) 1,328,313 (52) 512,349 (20) 189,759 (7) 2,553,909
Option 2 3.20 643,487 (42) 578,740 (38) 223,228 (15) 82,677 (5) 1,528,133
Option 5 2.90 812,457 (50) 525,259 (33) 202,600 (13) 75,037 (5) 1,615,353
Option 1 7.80 874,512 (29) 1,379,451 (46) 532,074 (18) 197,064 (7) 2,983,102
Option 4 2.00 892,931 (62) 363,861 (25) 140,347 (10) 51,980 (4) 1,449,119
a The situation in which there are no additional investments in infection control. CCS, community care services.
In the case of preventing nosocomial infection, a wider
range of costs that extend beyond the hospital sector should
be included in any infection control decision.4 Examples in-
clude the infection-related costs incurred by community-
based health services, and the infection-related private costs
incurred by individuals and family members.1,5-9 The question
of whether the costs of production losses (ie, lost time from
paid or unpaid work) due to infection should be included as
a cost in economic analyses is under debate and beyond the
scope of this article.3,10 In addition to assessing changes to all
relevant costs, the effect of infection control on health benefits
should also be estimated. The benefits of making investments
in the healthcare sector are often represented by quality-ad-
justed life years (QALYs).11,12 QALYs are the extra years of
life attributable to an intervention adjusted by a quality or
utility weight between 0 (death) and 1 (good health).13,14 For
example, an intervention that prolonged life by 10 years and
placed the patient in a health state valued at 0.7 generates 7
QALYs (ie, 10# 0.7). Torrance13 and Brazier14 provide good
reviews of QALYs.
Estimating the cost per QALY gained from a health pro-
gram is called cost-utility analysis and is a popular choice
among policy makers.15 Other approaches to economic eval-
uation in the context of infection control are reviewed by
Saint et al.16 The cost-utility approach provides results that
are easy to interpret, the relevant research methods are de-
scribed in the literature,3,17-19 and meaningful comparisons
can be made between quite different health programs. For
example the cost per QALY gained from a cancer-screening
program can be compared to the cost per QALY gained from
an infection control program. To date, those who champion
infection control have not produced many estimates of the
cost per QALY of existing or proposed infection control ac-
tivities. They should observe the example of those investi-
gators working in chronic diseases (eg, cardiopulmonary dis-
ease and cancer), who regularly publish estimates of the cost
per QALY for diagnostic, screening, and therapeutic inter-
ventions. We illustrate a method for estimating the cost per
QALY of infection control programs in the following pages.
an economic model of competing
infection control strategies
We extend an existing (hypothetical) model of 6 infection
control programs that prevent surgical site infection (SSI) in
50,000 patients undergoing total hip replacement (this is the
hospital administrator model2 mentioned earlier). The major
changes are the inclusion of a broader range of infection-
related costs and the inclusion of QALYs to represent the
health benefits of infection control.
Changes to Costs from Infection Control
The hospital administrator model2 has been extended to in-
clude a wider range of costs that are likely to change with
infection control. These have been studied by Plowman et
al.8,9 and Perencevich et al.,20 who found that patients with
infection used more health services in the community and
incurred greater private expenditures for pharmacy products
and travel costs. Because these costs increase with rates of
infection, effective prevention programs will generate cost
savings over and above those enjoyed by the hospital sector.
In Table 1, values are specified for all relevant cost outcomes
for a preintervention status quo infection control program
and 6 alternative infection control options. For each of these
7 options, values are included for the cost of infection control,
cost of infection to the hospital, cost of infection to com-
munity care services, and private costs of infection. We could
remain with the status quo, which represents current clinical
practice and a situation requiring no additional investment
in infection control. This decision imposes an SSI rate of 10%
and total cost outcomes of $2,675,000, of which 65% are
costs incurred by the hospital sector, 25% are costs incurred
by community care services, and 10% are private costs in-
curred by the individual. The decision to choose an alternative
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table 2. Hypothetical Data Used for Calculation of the Quality-
Adjusted Life Years (QALYs) Associated With Preventing a Case of
Surgical Site Infection (SSI)
Time period
Value, by SSI status
No SSI Fatal SSI Nonfatal SSI
Utility
weight QALY
Utility
weight QALY
Utility
weight QALY
2004
Jan-Mar 0.500 0.125 0.300 0.075 0.300 0.075
Apr-Jun 0.900 0.225 0.200 0.050 0.200 0.050
Jul-Sept 0.900 0.225 0.000 0.000 0.900 0.225
Oct-Dec 0.900 0.225 0.000 0.000 0.900 0.225
2005 0.900 0.900 0.000 0.000 0.900 0.900
2006 0.900 0.900 0.000 0.000 0.900 0.900
2007 0.900 0.900 0.000 0.000 0.900 0.900
2008 0.900 0.900 0.000 0.000 0.900 0.900
2009 0.900 0.900 0.000 0.000 0.900 0.900
2010 0.900 0.900 0.000 0.000 0.900 0.900
2011 0.900 0.900 0.000 0.000 0.900 0.900
2012 0.600 0.600 0.000 0.000 0.600 0.600
2013 0.000 0.000 0.000 0.000 0.000 0.000
Total QALYs … 7.7 … 0.125 … 7.475
infection control strategy, such as option 2, imposes a lower
rate of SSI (ie, cases are prevented) compared with the status
quo, and a different set of cost outcomes. With option 2, the
cost of prevention increases from $0 to $643,487. The costs
of SSI to the hospital sector are reduced from $1,750,000 to
$578,740, the costs of SSI to community care services are
reduced from $675,000 to $223,228, and the private costs of
SSI are reduced from $250,000 to $82,677. The most im-
portant change in cost outcomes is the difference between
the total costs of SSI with the status quo ($2,675,000) and after
the decision to invest in option 2 ($1,528,133). Total costs have
decreased by $1,146,867 (ie, $2,675,000 $1,528,133), and the
rate of infection has fallen by 6.8%. Assessing how costs change
in response to preventing infections is only half the story. To
complete a cost-utility analysis and provide decision makers
with answers to the questions posed in the introduction, we
must consider the changes in health benefits that arise from
infection control.
Changes in Health Benefits from Infection Control
Because SSI increases morbidity and mortality, effective in-
fection control programs will generate health benefits, and
these can be measured in QALYs. We demonstrate how to
estimate the number of QALYs gained from preventing in-
fections with the hypothetical data in Table 2. These data
relate to the example of SSI in hip replacement patients and
illustrate 2 outcomes: the QALY gain from preventing a fatal
SSI and the QALY gain from preventing a nonfatal SSI. All
patients receive a new hip in January 2004. A patient who
does not acquire an infection recuperates between January
and March 2004, during which time the patient occupies a
health state with a utility weight of 0.5. By April, the patient
has returned to a good health state valued at 0.9, suffering
only minor disability from their new hip, and remains there
until 2011. In 2012, the patient’s health deteriorates for other
reasons and the patient enters a health state with a utility
weight of 0.6; the patient has died by 2013. Since the surgery,
the patient has generated 7.7 QALYs in total: (0.25 years#
, or 0.125 6.750.5) (7.75 years# 0.9) (1 year# 0.6)
 0.6p 7.7. Contrast this scenario with a patient who ac-
quires an infection that proves fatal. Between January and
March 2004, the patient is very sick and occupies a health
state with a utility weight of 0.3. Between April and June
2004, the patient’s health deteriorates; the patient acquires a
secondary blood stream infection and dies of sepsis in the
intensive care unit on July 1, 2004. Before the patient dies,
the patient occupies a health state with a utility weight of
0.2. Since surgery, this unfortunate individual has endured 3
months in a health state valued at 0.3 and 3 months in a
health state valued at 0.2; in total, the patient generates 0.125
QALYs: , or(0.25 years# 0.3) (0.25 years# 0.2) 0.075
. The health benefits of an intervention that0.05p 0.125
prevents a fatal case of SSI is the difference between the 2
QALY scores: that is, QALYs. A patient7.7 0.125p 7.575
who acquires a nonfatal SSI also does badly between January
and June 2004. However, by July 2004, the patient has made
a full recovery, after which the patient occupies the same
health state and lives as long as patients who never acquired
an infection. In this scenario, the difference between the 2
QALY scores (the health benefit of prevention) is 0.225
QALYs, or . The accumulation of QALYs7.7 7.475p 0.225
over time for the no SSI scenario and the two SSI scenarios
is summarized in Figure 1.
A Model of the Costs and Benefits of Infection Control:
A Broader Perspective
The model in Figure 2 illustrates the cost and QALY outcomes
for the status quo and the 6 competing infection control
options under consideration. Cost comparisons are presented
in Table 1, and Table 2 shows the hypothetical data used for
calculating the QALYs gained from preventing fatal and non-
fatal SSIs, which are 7.575 and 0.225 QALYs, respectively. We
assume for this hypothetical model that 2.6% of patients who
acquire an SSI suffer a fatal infection and the remainder
survive. It is reassuring that, as Figure 2 shows, all infection
control options result in QALY gains relative to the status
quo. Differences in cost for all the prevention options are
calculated relative to the status quo, for which total costs were
$2,675,000. Although most of our options lead to cost savings,
option 1 leads to a cost increase from $2,675,000 (for the
status quo) to $2,983,102.
The first step in analyzing this model is to exclude all
options that produce higher costs and lower health benefits
than some available alternative. In other words, if an option
is less costly and more effective than an alternative (ie, it lies
This content downloaded from 23.235.32.0 on Wed, 21 Oct 2015 01:38:18 AM
All use subject to JSTOR Terms and Conditions
preventing hospital-acquired infection 181
figure 1. Profile of hypothetical health benefits for 3 infection scenarios. The area between the line marked “no SSI” and the line
marked “fatal SSI” represents the health benefits of preventing a fatal infection; the area between the line marked “no SSI” and the line
marked “nonfatal SSI” represents the health benefits of preventing a nonfatal infection.
lower than and to the right of that option in Figure 2), then
it dominates the other option and is always preferred to it.
On the basis of this rule, we see option 4 dominating, by
varying degrees, the status quo as well as options 1, 3, 6, 2,
and 5. In fact, it would be unethical not to invest in option
4. A decision to remain with the status quo or select a dom-
inated option (ie, 1, 3, 6, 2, and 5) creates a perverse situation
in which excess cost is incurred and infection rates are un-
necessarily high. There is no logic in simultaneously wasting
resources and harming patients! The second step in analyzing
this model is to consider 2 novel infection control strategies
that we now add to the model: option 7 and option 8. Al-
though both lead to substantial cost savings, compared with
the status quo, the relevant comparison is with the decision
to invest in option 4. Therefore, both options actually increase
costs. These cost increases are, however, compensated for by
gains in health benefits as represented by increasing QALYs.
Options 7 and 8 both lie higher and to the right of option
4 in Figure 2, indicating that they are more costly and more
effective, and both offer the opportunity to trade increased
costs for additional QALYs. The cost-effectiveness (or pro-
ductive efficiency) of this trade is represented by the gradients
of the dashed lines that join option 4 to options 7 and 8.
The gradient or incremental cost-effectiveness ratio for option
7, compared with option 4 is calculated as follows:
Cost  Cost DCoption 4 option 7ICERp p .
QALY QALY DEoption 4 option 7
So,
1,449,1191,629,478 180,359
ICERp p p$838/QALY .
1,6481,863 215
The gradient or incremental cost effectiveness ratio for option
8 as compared to option 4 is calculated as follows:
Cost  Cost DCoption 4 option 8ICERp p .
QALY QALY DEoption 4 option 8
So,
169,057
ICERp p $1,579/QALY .
107
QALYs can be achieved at lower cost by choosing option 7
over option 8, compared with option 4. We see that option
7, with a shallower gradient and lower ICER, is more cost-
effective (ie, more productively efficient) than option 8 (Fig-
ure 2). In a situation in which the decision maker’s budget
(or maximum willingness to pay for health benefits) is in-
sufficient to fund option 7 (the most expensive strategy), then
he or she should not choose the marginally cheaper, less
effective, and less cost-effective option 8. Instead the best
decision is a blended strategy in which some of the budget
is spent on option 7 and the remainder spent on option 4.
summary and conclusions
We posed 2 questions in the introduction. The first was
whether rates of infection should be reduced, and if so, by
how much. In the hypothetical model presented here, we
demonstrate that rates of infection should indeed be reduced.
The “lose-lose” situation of high costs and preventable in-
fections is absurd, but it may reflect current healthcare prac-
tices. Current infection rates impose costs on the healthcare
system, patients, and the wider economy, and inflict mor-
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figure 2. Hypothetical associated costs and quality-adjusted life years (QALYs) for all infection control options
bidity and risks of mortality on hospital patients. We dem-
onstrate that the decision not to choose option 4 is a difficult
position to defend. Whether rates of infection should be re-
duced further is not so clear cut. Reducing rates beyond the
level achieved with option 4 by using option 7 imposes extra
costs of $838 per QALY. We do not dismiss option 7 just
because it increases cost. Instead, Briggs21(p174) argues, “a trade
off must be made between the additional health outcomes
and the additional resources that must be committed to
achieve those outcomes.”
Whether or not $838 per QALY represents a good deal for
society depends on the preferences of the decision maker22
who must choose between option 7 and other uses of scarce
healthcare resources. Because healthcare resources are finite,
decision makers tend to constrain expenditures by choosing
to fund only those health programs that generate QALYs
below a certain ICER threshold. In the United States, this
figure is approximately $50,000 per QALY, but health econ-
omists are currently debating the maximum that decision
makers should pay for a QALY.23,24 The second question we
posed in the introduction was which infection control strat-
egies are cost-effective. We illustrated that, compared with
option 4, option 7 ($838 per QALY) was more cost-effective
than option 8 ($1,579 per QALY).
These conclusions differ from those drawn from the hos-
pital administrator model,2 in which the recommendation was
to invest in infection control only up to the point at which
cost increases were compensated for by cost savings. In the
present analysis, we recommended spending additional money
to obtain health benefits (ie, increasing costs to achieve extra
QALYs). The broader perspective, therefore, suggests greater
investment in infection control, compared with the recom-
mendations made on the basis of the hospital administrator
model.2
To build a broader perspective model, we need addition-
al data not included in the original hospital administrator
model. First, we require estimates of the nonhospital costs
attributable to infection. Plowman et al.8,9 reported data for
all patients discharged from a UK hospital and Perencevich
et al.20 described costs for SSIs occurring among patients dis-
charged from US hospitals. Second, we need to understand
the impact of infection on mortality risk. There is substantial
literature on this topic; a search of Medline that combines
the search terms “cross-infection” and “mortality” returns
130 citations. Although there is debate over the attributable
mortality risk, a careful review might provide evidence of the
likely effect of infection. If not, new studies are required to
identify the independent effect of infection on mortality risks.
Third, we need utility weights that accurately value the health
states that individuals with infection occupy and the asso-
ciated duration of these health states. The cost-effectiveness
analysis registry managed by the Harvard Center for Risk
Analysis summarizes utility weights for health states reported
in 228 peer-reviewed publications. Among these, we found
1 study that valued health states associated with urinary tract
infections25 and 2 studies that valued health states associated
with infections in patients who underwent prosthetic joint
replacement.26,27 This suggests a need for further research that
uses preference-based methods to elicit utility valuations of
the health states associated with the numerous manifestations
of infection. On the basis of these data, decision models to
evaluate the changes in cost and health benefits (QALYs)
associated with prevention programs can be built.
This article represents a starting point for full economic
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evaluations of infection control practices. Developing realistic
models of how costs and health benefits change with various
infection control strategies will be challenging. Multiple
sources of evidence will have to be synthesized into a single
economic model, as no randomized controlled trial could be
designed to test all competing infection control interventions;
the cost and ethical hurdles alone would be insurmountable.
However, methods for data synthesis and handling uncer-
tainty in economic evaluation have progressed rapidly in re-
cent years.28-30 Also, researchers are considering the dynamic
nature of transmission; some types of infection are sensitive
to admission and discharge rates, overcrowding in wards, and
routine hand washing practices among healthcare workers.31-33
Although these techniques add complexity to the model-
building process, they also benefit the decision-making pro-
cess by providing clear and realistic results.
In conclusion, we argue that the infection control com-
munity should develop appropriate economic models for in-
fection control programs. Our intuition is that additional
investments in infection control offer good value for money
compared with many of the other activities currently pursued
in healthcare services. The research to test this intuition is
currently missing from the policy and clinical literature, al-
though Stone et al.34 did review the meager amount of cost-
effectiveness data on infection control. These omissions may
partly explain the complaints of insufficient funding for in-
fection control.35-38 Infection control professionals should use
economic arguments to market their interventions to those
who control healthcare budgets. If programs are cost saving
and prevent infections, then the decision not to invest is
unethical. If they generate cheap QALYs, as compared with
other uses of healthcare resources, then the arguments for
funding those infection control programs are strong. If, how-
ever, the cost per QALY for prevention is high, it will be more
difficult to argue for further investment. The answers lie in
doing the research!
APPENDIX
A formal definition of an incremental cost-effectiveness ratio
is given by this simple formula:
C  C DCI EPIncremental cost-effectiveness ratio p p
E  E DEI EP
where represents a measure of economic costs after theC I
intervention has been implemented, represents a measureC EP
of economic costs associated with an existing practice or a
reference case (ie, before implementation), represents theE I
level of health benefits after the intervention has been im-
plemented, and represents the level of health benefitsE EP
associated with an existing practice or a reference case (ie,
before implementation). Therefore, represents the changeDC
in cost due to the intervention, and represents the changeDE
in health benefits due to the intervention. The ratio of DC
and is interpreted as the amount by which cost changesDE
to obtain a unit of health effect, and this is the incremental
cost-effectiveness ratio.
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